The agreement aims to develop integrated technology for large-scale exosome production.
Sartorius BIA Separations (BIA), a bio-chromatography company, and Exopharm, a company focused on medicines using exosomes, or extracellular vesicles, announced on Nov. 22, 2022 that they have entered into a formal collaboration. The companies have signed a Material Transfer Agreement that aims to use Exopharm’s patented LEAP technology alongside BIA’s Convective Interaction Media chromatography for improved large-scale therapeutic exosome production and commercialization.
According to a company press release, exosomes have advantages over alternative nanoparticle delivery technologies, as they are non-toxic, efficient at delivering RNA cargoes into cells, and able to do so without eliciting an immune response. Exosomes can also be engineered to provide specific delivery as well as repeated dosing.
“BIA sees the potential in exosomes for new and innovative therapeutic applications and understands that purification of exosomes has held back their adoption as a non-viral drug-delivery technology,” said Aleš Strancar, co-founder and managing director of BIA, in the release. “We believe that BIA’s CIM monolith technology and Exopharm’s exosome-specific LEAP ligands can work synergistically together to enhance specificity, efficiency and capacity of industrial exosome purification processes. This work with Exopharm has the potential to be a game-changer in the emerging exosome field.”
Source: Sartorius BIA Separations
Kyron.bio Raises €5.5M to Advance Precision Glycan Engineering for Safer Antibody Therapeutics
May 28th 2025Funding will support the company’s efforts to refine its proprietary glycan-engineering platform, expand its scientific and operational team, and advance preclinical studies of its engineered biologics.
New Cancer Research and Treatment Center in Development in London
May 1st 2025Aviva Capital Partners and developer Socius are investing £1 billion in a 12-acre site to be located at the London Cancer Hub next to The Institute of Cancer Research, London and The Royal Marsden NHS Foundation Trust’s Sutton site.